60 results
8-K
EX-99.1
DNLI
Denali Therapeutics Inc
27 Feb 24
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8:07am
in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual and Quarterly Reports on Forms 10
8-K
EX-10.1
DNLI
Denali Therapeutics Inc
27 Feb 24
Denali Therapeutics Announces $500 million Private Placement Equity Financing
8:03am
substances, wastes, pollutants, contaminants or the protection of human health or safety, the environment or natural resources (collectively, “Environmental
8-K
EX-99.1
DNLI
Denali Therapeutics Inc
8 Jan 24
Regulation FD Disclosure
8:06am
financial results in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual and Quarterly
8-K
EX-99.1
t2ipquxt
7 Nov 23
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
EX-99.1
csjl9o 32jsed
8 Aug 23
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
EX-99.1
qtal4wf4sunwq6y
8 May 23
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
4:03pm
8-K
EX-99.1
by8b210tq 5dviko1uu
3 Nov 22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
4:05pm
8-K
EX-1.1
4q834drc
20 Oct 22
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
4:58pm
424B5
04my3l
20 Oct 22
Prospectus supplement for primary offering
4:57pm
8-K
EX-99.3
4j5kpa61e7yhhl4
18 Oct 22
Denali Therapeutics Announces Proposed Offering of Common Stock
5:09pm
424B5
wr6c10 f88vgs
18 Oct 22
Prospectus supplement for primary offering
5:08pm
8-K
EX-99.1
d5a 3jbnn5n
8 Aug 22
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4:03pm